Trial Profile

One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary) ; Antiasthmatics; Prednisolone; Prednisolone; Prednisolone; Prednisone; Prednisone; Prednisone
Indications Asthma
Focus Adverse reactions; Therapeutic Use
Acronyms EXCURSION; Liberty Asthma Excursion
Sponsors Sanofi

Most Recent Events

23 Dec 2025 According to Regeneron pharmaceuticals media release, based on data from this study the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma.
24 Apr 2025 Status changed from active, no longer recruiting to completed.
12 Sep 2024 This trial has been completed in Hungary.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com